Puma Biotechnology Announces Presentation of Findings From a Phase II Study of Alisertib in Endocrine-Resistant Metastatic Breast Cancer (Tbcrc 041)
Puma Biotechnology宣佈介紹Alisertib治療耐內分泌轉移性乳腺癌的II期研究結果(Tbcrc 041)
Puma Biotechnology Announces Presentation of Findings From a Phase II Study of Alisertib in Endocrine-Resistant Metastatic Breast Cancer (Tbcrc 041)
Puma Biotechnology宣佈介紹Alisertib治療耐內分泌轉移性乳腺癌的II期研究結果(Tbcrc 041)
譯文內容由第三人軟體翻譯。